MoonLake Immunotherapeutics
MLTX
$39.65
$0.982.53%
Weiss Ratings | MLTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Very Weak | |||
Risk Index | Weak | |||
Risk Grade | D | |||
Reward Grade | E | |||
Rating Factors | MLTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Very Weak | |||
Efficiency Index | Very Weak | |||
Solvency Index | Excellent | |||
Total Return Index | Fair | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | MLTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 0.61 | |||
Price History | MLTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | 4.25% | |||
30-Day Total Return | -9.16% | |||
60-Day Total Return | -29.57% | |||
90-Day Total Return | -14.55% | |||
Year to Date Total Return | -25.98% | |||
1-Year Total Return | -18.35% | |||
2-Year Total Return | 85.98% | |||
3-Year Total Return | 298.89% | |||
5-Year Total Return | -- | |||
52-Week High % Change | -33.63% | |||
52-Week Low % Change | 5.89% | |||
Price | MLTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $58.26 | |||
52-Week Low Price | $36.52 | |||
52-Week Low Price (Date) | Mar 11, 2025 | |||
52-Week High Price (Date) | Dec 17, 2024 | |||
Valuation | MLTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 2.45B | |||
Enterprise Value | 2.01B | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -1.89 | |||
Earnings Per Share Growth | 147.85% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | -- | |||
Price/Book (Q) | 5.46 | |||
Enterprise Value/Revenue (TTM) | -- | |||
Price | $39.65 | |||
Enterprise Value/EBITDA (TTM) | -14.17 | |||
Enterprise Value/EBIT | -14.04 | |||
Market Cap Category | Mid Cap | |||
Dividends and Shares | MLTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 63.07M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | MLTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 41 415108022 | |||
Address | -- | |||
Website | www.moonlaketx.com | |||
Country | Switzerland | |||
Year Founded | 2021 | |||
Profitability | MLTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -- | |||
Profit Margin | -- | |||
Management Effectiveness | MLTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -17.81% | |||
Return on Equity | -- | |||
Income Statement | MLTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | -- | |||
Total Revenue (TTM) | -- | |||
Revenue Per Share | -- | |||
Gross Profit (TTM) | -- | |||
EBITDA (TTM) | -141.71M | |||
EBIT (TTM) | -143.09M | |||
Net Income (TTM) | -118.94M | |||
Net Income Avl. to Common (TTM) | -118.94M | |||
Total Revenue Growth (Q YOY) | -- | |||
Earnings Growth (Q YOY) | -488.23% | |||
EPS Diluted (TTM) | -1.89 | |||
EPS Diluted Growth (Q YOY) | -482.68% | |||
Balance Sheet | MLTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 448.03M | |||
Cash Per Share (Q) | $7.10 | |||
Total Current Assets (Q) | 474.29M | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | 453.39M | |||
Current Ratio (Q) | 21.113 | |||
Book Value Per Share (Q) | $7.08 | |||
Total Assets (Q) | 477.93M | |||
Total Current Liabilities (Q) | 22.46M | |||
Total Debt (Q) | 2.83M | |||
Total Liabilities (Q) | 24.54M | |||
Total Common Equity (Q) | 446.83M | |||
Cash Flow | MLTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | -205.60M | |||
Cash from Financing (TTM) | 51.31M | |||
Net Change in Cash (TTM) | -270.74M | |||
Levered Free Cash Flow (TTM) | -92.06M | |||
Cash from Operations (TTM) | -116.59M | |||